We are financed by world class investors

We are ambitious – The OMass pipeline is weighted towards programs addressing homogeneous, specialty care patient populations aligned with our intent to build integrated development and commercialization capabilities. Our pipeline also includes targets addressing large indications where OMass expects to partner in order to realize the full value of our programs.

Supportive and experienced investors – Originally a spinout from Oxford University, OMass is backed by a top-tier investor syndicate.

Syncona's purpose is to invest to extend and enhance human life. Syncona does this by founding and building a portfolio of global leaders in life science to deliver transformational treatments to patients in areas of high unmet need.

Oxford Science Enterprises is a science business builder. They build world-changing businesses, bringing Oxford science to the world faster.

GV provides venture capital funding to bold new companies. Across the fields of life science, enterprise technology, consumer products and services, and frontier technology, GV's portfolio companies aim to improve lives and transform industries.

Northpond Ventures is a multi-billion dollar science-driven venture capital firm based in Cambridge, MA; San Francisco, CA; and Bethesda, MD. Northpond has been named one of the three most active lead biotech investors in 2021 by Crunchbase, and the most active lead investor in life science solutions and molecular diagnostics by Silicon Valley Bank.

Sanofi Ventures is the corporate venture capital arm of Sanofi. Sanofi Ventures invests in early-stage biotech and digital health companies with innovative ideas and transformative new products and technologies of strategic interest to Sanofi.